NZ629700A - Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy - Google Patents

Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Info

Publication number
NZ629700A
NZ629700A NZ629700A NZ62970013A NZ629700A NZ 629700 A NZ629700 A NZ 629700A NZ 629700 A NZ629700 A NZ 629700A NZ 62970013 A NZ62970013 A NZ 62970013A NZ 629700 A NZ629700 A NZ 629700A
Authority
NZ
New Zealand
Prior art keywords
cancer
treatment
vaccines
compositions
mammalian
Prior art date
Application number
NZ629700A
Other languages
English (en)
Inventor
Graham Vesey
Ross Arthur Davey
Christopher John Weir
Original Assignee
Cell Ideas Pty Ltd
Northern Sydney Local Health Distr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905667A external-priority patent/AU2012905667A0/en
Priority claimed from AU2013203806A external-priority patent/AU2013203806B2/en
Application filed by Cell Ideas Pty Ltd, Northern Sydney Local Health Distr filed Critical Cell Ideas Pty Ltd
Publication of NZ629700A publication Critical patent/NZ629700A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ629700A 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy NZ629700A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012905667A AU2012905667A0 (en) 2012-12-24 Vaccines for treatment of cancer
AU2012905669A AU2012905669A0 (en) 2012-12-24 Vaccine booster
AU2013203806A AU2013203806B2 (en) 2012-12-24 2013-04-11 Vaccines for the treatment or prevention of cancer
AU2013903592A AU2013903592A0 (en) 2013-09-18 Vaccines for the treatment or prevention of cancer
PCT/AU2013/001523 WO2014100857A1 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Publications (1)

Publication Number Publication Date
NZ629700A true NZ629700A (en) 2017-01-27

Family

ID=53547734

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629700A NZ629700A (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Country Status (7)

Country Link
US (2) US10357538B2 (cg-RX-API-DMAC7.html)
EP (2) EP2934578B1 (cg-RX-API-DMAC7.html)
JP (2) JP6286445B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013370932B2 (cg-RX-API-DMAC7.html)
CA (1) CA2934958A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ629700A (cg-RX-API-DMAC7.html)
WO (1) WO2014100857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934578B1 (en) * 2012-12-24 2018-11-21 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
WO2017136539A1 (en) 2016-02-04 2017-08-10 Hare Joshua M Mesenchymal stem cells as vaccine adjuvants and methods for using the same
KR20190003456A (ko) * 2016-04-01 2019-01-09 아프세스 게엠베하 & 씨오. 카게 면역치료의 항-종양 활성을 높이기 위한 중간엽 줄기세포
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN111868085B (zh) * 2018-03-19 2024-11-05 瑞泽恩制药公司 微芯片毛细管电泳测定法及试剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) * 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6379671B1 (en) * 1996-08-19 2002-04-30 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
EP1015024A1 (en) * 1997-09-20 2000-07-05 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2477411A1 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas Local production and/or delivery of anti-cancer agents by stromal cell precursors
ES2395126T3 (es) 2003-02-28 2013-02-08 Agenus Inc. Uso de lectinas para promover la oligomerización de glicoproteínas y de moléculas antigénicas
AU2003903317A0 (en) 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US20050239897A1 (en) 2004-03-22 2005-10-27 Pittenger Mark F Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
CN1887296B (zh) * 2006-07-31 2011-05-25 南京大学生物制药工程研究中心 一种诱导抗肿瘤免疫的方法及其在制药中的应用
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US8771705B2 (en) * 2009-07-30 2014-07-08 Healthbanks Biotech Co., Ltd. Combination of protein vaccine and mesenchymal stem cells for treating cancer
US20120263685A1 (en) * 2009-10-08 2012-10-18 Rnl Bio Co., Ltd Anti-tumor composition comprising human-derived adult stem cells
WO2011060244A1 (en) * 2009-11-12 2011-05-19 The Texas A & M University System Spheroidal aggregates of mesenchymal stem cells
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
WO2013040649A1 (en) 2011-09-23 2013-03-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
EP2934578B1 (en) * 2012-12-24 2018-11-21 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Also Published As

Publication number Publication date
WO2014100857A1 (en) 2014-07-03
EP3446708A1 (en) 2019-02-27
JP2018111695A (ja) 2018-07-19
JP6286445B2 (ja) 2018-02-28
EP2934578B1 (en) 2018-11-21
EP2934578A1 (en) 2015-10-28
AU2013370932A1 (en) 2015-07-09
US20190358291A1 (en) 2019-11-28
US20150343040A1 (en) 2015-12-03
CA2934958A1 (en) 2014-07-03
WO2014100857A8 (en) 2014-11-06
WO2014100857A9 (en) 2015-07-09
US10357538B2 (en) 2019-07-23
JP2016505003A (ja) 2016-02-18
EP2934578A4 (en) 2016-07-13
AU2013370932B2 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
IN2014KN00848A (cg-RX-API-DMAC7.html)
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
IN2014KN02933A (cg-RX-API-DMAC7.html)
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TN2015000396A1 (en) Antibody drug conjugates
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
MX2016008160A (es) Metodos para dar forma a material fibroso y composiciones de tratamiento de este.
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
TN2012000555A1 (en) Antibodies to human gdf8
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
UA115030C2 (uk) Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа)
MX2015003985A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
NZ629700A (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX2016008159A (es) Metodos para dar forma a material fibroso y composiciones de tratamiento para este.
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX360774B (es) Antagonistas de progesterona.
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
PH12015501360A1 (en) Bmp-6 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2018 BY CPA GLOBAL

Effective date: 20171110

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2019 BY CPA GLOBAL

Effective date: 20181108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2020 BY CPA GLOBAL

Effective date: 20191107

LAPS Patent lapsed